175 related articles for article (PubMed ID: 37327320)
1. Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression.
Lheureux S; Prokopec SD; Oldfield LE; Gonzalez-Ochoa E; Bruce JP; Wong D; Danesh A; Torti D; Torchia J; Fortuna A; Singh S; Irving M; Marsh K; Lam B; Speers V; Yosifova A; Oaknin A; Madariaga A; Dhani NC; Bowering V; Oza AM; Pugh TJ
Clin Cancer Res; 2023 Sep; 29(18):3706-3716. PubMed ID: 37327320
[TBL] [Abstract][Full Text] [Related]
2. EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression.
Lheureux S; Oaknin A; Garg S; Bruce JP; Madariaga A; Dhani NC; Bowering V; White J; Accardi S; Tan Q; Braunstein M; Karakasis K; Cirlan I; Pedersen S; Li T; Fariñas-Madrid L; Lee YC; Liu ZA; Pugh TJ; Oza AM
Clin Cancer Res; 2020 Aug; 26(16):4206-4215. PubMed ID: 32444417
[TBL] [Abstract][Full Text] [Related]
3. Diverse
Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
[No Abstract] [Full Text] [Related]
4. Mutation profiles in circulating cell-free DNA predict acquired resistance to olaparib in high-grade serous ovarian carcinoma.
Hu D; Guo E; Yang B; Qin X; Fu Y; Fan J; Zhuang X; Yao Q; Lu F; Li W; Xiao R; Wu X; Yang X; Wang Z; Liu C; You L; Zang R; Zhou Q; Zhao W; Chen G; Sun C
Cancer Sci; 2022 Aug; 113(8):2849-2861. PubMed ID: 35661486
[TBL] [Abstract][Full Text] [Related]
5. Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of
Quigley D; Alumkal JJ; Wyatt AW; Kothari V; Foye A; Lloyd P; Aggarwal R; Kim W; Lu E; Schwartzman J; Beja K; Annala M; Das R; Diolaiti M; Pritchard C; Thomas G; Tomlins S; Knudsen K; Lord CJ; Ryan C; Youngren J; Beer TM; Ashworth A; Small EJ; Feng FY
Cancer Discov; 2017 Sep; 7(9):999-1005. PubMed ID: 28450426
[TBL] [Abstract][Full Text] [Related]
6. PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports.
Collot T; Niogret J; Carnet M; Chevrier S; Humblin E; Favier L; Bengrine-Lefevre L; Desmoulins I; Arnould L; Boidot R
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33236159
[TBL] [Abstract][Full Text] [Related]
7. Investigation of PARP Inhibitor Resistance Based on Serially Collected Circulating Tumor DNA in Patients With BRCA-Mutated Ovarian Cancer.
Kim YN; Shim Y; Seo J; Choi Z; Lee YJ; Shin S; Kim SW; Kim S; Choi JR; Lee JY; Lee ST
Clin Cancer Res; 2023 Jul; 29(14):2725-2734. PubMed ID: 37067525
[TBL] [Abstract][Full Text] [Related]
8. Identification of Somatically Acquired
Vidula N; Dubash T; Lawrence MS; Simoneau A; Niemierko A; Blouch E; Nagy B; Roh W; Chirn B; Reeves BA; Malvarosa G; Lennerz J; Isakoff SJ; Juric D; Micalizzi D; Wander S; Spring L; Moy B; Shannon K; Younger J; Lanman R; Toner M; Iafrate AJ; Getz G; Zou L; Ellisen LW; Maheswaran S; Haber DA; Bardia A
Clin Cancer Res; 2020 Sep; 26(18):4852-4862. PubMed ID: 32571788
[TBL] [Abstract][Full Text] [Related]
9.
Lin KK; Harrell MI; Oza AM; Oaknin A; Ray-Coquard I; Tinker AV; Helman E; Radke MR; Say C; Vo LT; Mann E; Isaacson JD; Maloney L; O'Malley DM; Chambers SK; Kaufmann SH; Scott CL; Konecny GE; Coleman RL; Sun JX; Giordano H; Brenton JD; Harding TC; McNeish IA; Swisher EM
Cancer Discov; 2019 Feb; 9(2):210-219. PubMed ID: 30425037
[TBL] [Abstract][Full Text] [Related]
10. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
Ivy SP; Liu JF; Lee JM; Matulonis UA; Kohn EC
Expert Opin Investig Drugs; 2016; 25(5):597-611. PubMed ID: 26899229
[TBL] [Abstract][Full Text] [Related]
11. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
[No Abstract] [Full Text] [Related]
12. Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion
Vidula N; Rich TA; Sartor O; Yen J; Hardin A; Nance T; Lilly MB; Nezami MA; Patel SP; Carneiro BA; Fan AC; Brufsky AM; Parker BA; Bridges BB; Agarwal N; Maughan BL; Raymond VM; Fairclough SR; Lanman RB; Bardia A; Cristofanilli M
Clin Cancer Res; 2020 Jun; 26(11):2546-2555. PubMed ID: 32034076
[TBL] [Abstract][Full Text] [Related]
13. Olaparib-Resistant
Biegała Ł; Gajek A; Marczak A; Rogalska A
Cells; 2023 Mar; 12(7):. PubMed ID: 37048111
[TBL] [Abstract][Full Text] [Related]
14. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
Waks AG; Cohen O; Kochupurakkal B; Kim D; Dunn CE; Buendia Buendia J; Wander S; Helvie K; Lloyd MR; Marini L; Hughes ME; Freeman SS; Ivy SP; Geradts J; Isakoff S; LoRusso P; Adalsteinsson VA; Tolaney SM; Matulonis U; Krop IE; D'Andrea AD; Winer EP; Lin NU; Shapiro GI; Wagle N
Ann Oncol; 2020 May; 31(5):590-598. PubMed ID: 32245699
[TBL] [Abstract][Full Text] [Related]
15. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract][Full Text] [Related]
16. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
[TBL] [Abstract][Full Text] [Related]
17. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
[TBL] [Abstract][Full Text] [Related]
18. Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification.
Gasimli K; Raab M; Tahmasbi Rad M; Kurunci-Csacsko E; Becker S; Strebhardt K; Sanhaji M
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142803
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.
Lheureux S; Lai Z; Dougherty BA; Runswick S; Hodgson DR; Timms KM; Lanchbury JS; Kaye S; Gourley C; Bowtell D; Kohn EC; Scott C; Matulonis U; Panzarella T; Karakasis K; Burnier JV; Gilks CB; O'Connor MJ; Robertson JD; Ledermann J; Barrett JC; Ho TW; Oza AM
Clin Cancer Res; 2017 Aug; 23(15):4086-4094. PubMed ID: 28223274
[No Abstract] [Full Text] [Related]
20. The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma.
Morra F; Merolla F; Damia G; Ricci F; Varricchio S; Ilardi G; Arenare L; Califano D; Napolitano V; Fruscio R; Melillo RM; Palazzo L; Celetti A
J Exp Clin Cancer Res; 2022 Aug; 41(1):245. PubMed ID: 35964058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
